TRIDENT Clinical Trial featured in WashU’s Medical News Hub

A new $3 million grant — from the National Cancer Institute (NCI) of the National Institutes of Health (NIH) — is supporting a phase 2 clinical trial to investigate an osteoporosis drug for its potential to lower breast density in women with dense breasts. Women with dense breasts have four- to six-times higher risk of developing breast cancer than women with lower breast density. The average woman has a one in eight chance of developing breast cancer over an 80-year life span.


“’For women who have not yet gone through menopause, we do not have good preventative measures against breast cancer,’” said principal investigator